Medical Device | February 28, 2022
Europe clears blood test to predict Alzheimer’s disease
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
The aim is to create an awareness programme that will drive diabetic patients to get their eyes tested regularly
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
The process is completed with the help of a balloon at a low temperature so that other cells are undamaged and the patient can return home the next day
Subscribe To Our Newsletter & Stay Updated
